The Current Place of DPP4 Inhibitors in the Evolving Landscape of Type 2 Diabetes Management: Is It Time to Bid Adieu?

• Published in: American journal of cardiovascular drugs : drugs, devices, and other interventions Vol. 23; no. 6; pp. 601 - 608
• Main Authors: Koufakis, Theocharis, Zografou, Ioanna, Doumas, Michael, Kotsa, Kalliopi
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.11.2023; Springer Nature B.V
• Subjects: Antidiabetics; Body mass index; Cardiology; Cost analysis; Current Opinion; Diabetes; Drug dosages; Glucagon; Glucose; Hypoglycemia; Medicine; Medicine & Public Health; Mortality; Patients; Pharmacology/Toxicology; Pharmacotherapy; Polypeptides; Weight control
• ISSN: 1175-3277; 1179-187X
• DOI: 10.1007/s40256-023-00610-8

During the last decade, the landscape of type 2 diabetes (T2D) management has been completely transformed, moving from a glucose-centric perspective to a holistic approach that also takes into account weight control and organ protection. Dipeptidyl peptidase-4 inhibitors (DPP4i) are oral agents that have been used for the treatment of T2D for almost 20 years. Although they present an excellent safety profile, including the risk of hypoglycemia, they lack the spectacular cardiorenal benefits and weight-loss effects of the newer antidiabetic agents. This poses the question of whether they still deserve a place in the arsenal of drugs against T2D. In this article, we use a hypothetical case scenario to illustrate possible patient profiles where DPP4i could prove useful in the clinical setting. We discuss the advantages and disadvantages of the category, focusing on glycemic control, weight management, and cardiorenal protection, which are the pillars of modern T2D management, also considering its safety profile and cost-effectiveness. We conclude that in most cases, DPP4i present a more favorable risk–benefit ratio compared to sulfonylureas, which are still widely prescribed throughout the world. We also suggest that future research should clarify the reasons behind the contradictory findings between human and animal studies on cardiorenal effects of the class and identify subgroups of patients who would derive most benefit with DPP4i treatment.